Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Recommendation of “Moderate Buy” from Brokerages

Cellebrite DI Ltd. (NASDAQ:CLBT) has been assigned a consensus rating of “Moderate Buy” from the five research firms that are presently covering the firm, Marketbeat reports. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $22.50.

Several equities research analysts have recently commented on the stock. Needham & Company LLC lowered their price objective on shares of Cellebrite DI from $24.00 to $18.00 and set a “buy” rating for the company in a research note on Thursday, February 12th. Wall Street Zen raised Cellebrite DI from a “sell” rating to a “hold” rating in a research report on Sunday, March 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Cellebrite DI in a research note on Monday, December 29th.

Cellebrite DI Stock Up 0.7%

CLBT opened at $13.88 on Thursday. Cellebrite DI has a 52-week low of $11.76 and a 52-week high of $20.53. The company has a market cap of $3.46 billion, a P/E ratio of 44.77, a price-to-earnings-growth ratio of 2.11 and a beta of 1.27. The firm’s 50-day moving average price is $14.36 and its 200-day moving average price is $16.67.

Cellebrite DI (NASDAQ:CLBT) last released its earnings results on Wednesday, February 11th. The company reported $0.14 EPS for the quarter, hitting analysts’ consensus estimates of $0.14. The company had revenue of $128.82 million during the quarter, compared to analysts’ expectations of $126.07 million. Cellebrite DI had a net margin of 16.47% and a return on equity of 20.43%. Cellebrite DI’s revenue for the quarter was up 28.8% on a year-over-year basis. During the same period last year, the business earned $0.10 EPS. On average, research analysts anticipate that Cellebrite DI will post 0.3 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CLBT. Venturi Wealth Management LLC lifted its holdings in shares of Cellebrite DI by 5.0% during the third quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock worth $272,000 after purchasing an additional 700 shares during the period. CWM LLC increased its holdings in Cellebrite DI by 85.7% in the 3rd quarter. CWM LLC now owns 1,560 shares of the company’s stock worth $29,000 after buying an additional 720 shares during the period. Towarzystwo Funduszy Inwestycyjnych PZU SA raised its position in Cellebrite DI by 81.0% during the 4th quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA now owns 1,900 shares of the company’s stock worth $34,000 after buying an additional 850 shares during the last quarter. Blue Trust Inc. raised its position in Cellebrite DI by 4.0% during the 3rd quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after buying an additional 898 shares during the last quarter. Finally, SkyView Investment Advisors LLC lifted its stake in Cellebrite DI by 2.6% during the 2nd quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock valued at $597,000 after acquiring an additional 970 shares during the period. 45.88% of the stock is currently owned by hedge funds and other institutional investors.

About Cellebrite DI

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.